Regeneron Pharmaceuticals (REGN) Enterprise Value (2009 - 2026)

Regeneron Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$8.8 billion for Q1 2026.

• On a quarterly basis, Enterprise Value fell 4.84% year-over-year to -$8.8 billion in Q1 2026; TTM through Mar 2026 was -$8.8 billion, a 4.84% decrease from a year earlier, with the FY2025 full-year figure at -$8.6 billion, up 4.52% from the prior year.
• Enterprise Value eased to -$8.8 billion in Q1 2026 per REGN's latest filing, from -$8.6 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$7.0 billion in Q3 2022 and bottomed at -$10.8 billion in Q4 2023.
• The 5-year median for Enterprise Value is -$8.8 billion (2026), against an average of -$8.8 billion.
• Across the five-year window, Enterprise Value plunged 101.23% in 2022 and grew 23.85% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$7.7 billion in 2022, then tumbled by 40.07% to -$10.8 billion in 2023, then grew by 16.9% to -$9.0 billion in 2024, then climbed by 4.52% to -$8.6 billion in 2025, then dropped by 1.73% to -$8.8 billion in 2026.
• Per Business Quant, the three latest REGN Enterprise Value figures stand at -$8.8 billion (Q1 2026), -$8.6 billion (Q4 2025), and -$8.4 billion (Q3 2025).